NCT00555048 · ADVERSE EVENTS

Adverse events

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer · Source last updated 2017-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Alemtuzumab Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation	0 / 1	0 / 1	Not reported / Not reported

Group identifiers: EG000: Alemtuzumab

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation
id
EG000
other Num Affected
0
other Num At Risk
1
serious Num Affected
0
serious Num At Risk
1
title
Alemtuzumab

frequency Threshold

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice